Peter Stæhr

2.1k total citations · 1 hit paper
35 papers, 1.5k citations indexed

About

Peter Stæhr is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Physiology. According to data from OpenAlex, Peter Stæhr has authored 35 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Physiology. Recurrent topics in Peter Stæhr's work include Metabolism, Diabetes, and Cancer (12 papers), Diet and metabolism studies (6 papers) and Adipose Tissue and Metabolism (5 papers). Peter Stæhr is often cited by papers focused on Metabolism, Diabetes, and Cancer (12 papers), Diet and metabolism studies (6 papers) and Adipose Tissue and Metabolism (5 papers). Peter Stæhr collaborates with scholars based in Denmark, United States and United Kingdom. Peter Stæhr's co-authors include Henning Beck‐Nielsen, Ole Hother‐Nielsen, Aase Handberg, Henrik Daa Schrøder, Michael Gaster, Patrick W. Serruys, Yoshinobu Onuma, Kurt Højlund, Jens J. Holst and Susan Veldhof and has published in prestigious journals such as The Lancet, Diabetes and Stroke.

In The Last Decade

Peter Stæhr

33 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

2014 393 citations Patrick W. Serruys, Susan Veldhof et al. profile →

Peers

Countries citing papers authored by Peter Stæhr

Since Specialization

Citations

This map shows the geographic impact of Peter Stæhr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Stæhr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Stæhr more than expected).

Fields of papers citing papers by Peter Stæhr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Stæhr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Stæhr. The network helps show where Peter Stæhr may publish in the future.

Co-authorship network of co-authors of Peter Stæhr

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Stæhr. A scholar is included among the top collaborators of Peter Stæhr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Stæhr. Peter Stæhr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between cardiac rehabilitation and LDL-levels, adherence to guideline-recommended medication and mortality rate after myocardial infarction 2025 ·International Journal of Cardiology Cardiovascular Risk and Prevention ·(unknown), (unknown), Kristian Kragholm, Lauge Østergaard, Peter Stæhr, Gitte Nielsen, (unknown)	1
2	Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin‐treated diabetes: A randomised, open‐label, crossover trial 2025 ·Diabetes Obesity and Metabolism ·(unknown), Simon Lebech Cichosz, Peter Stæhr, Peter Vestergaard, Asbjørn Mohr Drewes, Filip K. Knop, Morten Hasselstrøm Jensen, Søren Schou Olesen	0
3	Hyperpolarized [1-13C]pyruvate cardiovascular magnetic resonance imaging identifies metabolic phenotypes in patients with heart failure 2024 ·Journal of Cardiovascular Magnetic Resonance ·(unknown), Esben Søvsø Szocska Hansen, Nikolaj Bøgh, Lotte Bonde Bertelsen, Rasmus Stilling Tougaard, Peter Stæhr, Christoffer Laustsen, Henrik Wiggers	5
4	Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study 2022 ·The Lancet Regional Health - Europe ·(unknown), Julie Andersen, Mariam Elmegaard Malik, Christian Selmer, Peter Gæde, Peter Stæhr, Mark A. Hlatky, Emil Loldrup Fosbøl, Lars Køber, Christian Torp‐Pedersen, Gunnar Gislason, Thomas Alexander Gerds, Morten Schou, Niels Eske Bruun, Anne‐Christine Ruwald	36
5	Socioeconomic position and first-time major cardiovascular event in patients with type 2 diabetes: a Danish nationwide cohort study 2021 ·European Journal of Preventive Cardiology ·(unknown), Bochra Zareini, Julie Andersen, (unknown), Tina B Hansen, Christian Selmer, Morten Schou, Peter Gæde, Peter Stæhr, Mark A. Hlatky, Christian Torp‐Pedersen, Gunnar Gislason, Thomas Alexander Gerds, Niels Eske Bruun, Anne‐Christine Ruwald	12
6	Clinical features and prognosis of patients with acute non-specific chest pain in emergency and cardiology departments after the introduction of high-sensitivity troponins: a prospective cohort study 2017 ·BMJ Open ·(unknown), Hans Mickley, Axel Cosmus Pyndt Diederichsen, Annmarie Touborg Lassen, Thomas Lund Sørensen, (unknown), Peter Stæhr, Christian Backer Mogensen	5
7	Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation 2017 ·JACC: Cardiovascular Interventions ·Dariusz Dudek, Łukasz Rzeszutko, Yoshinobu Onuma, Yohei Sotomi, (unknown), Susan Veldhof, Divine Ediebah, Peter Stæhr, Wojciech Zasada, Krzysztof Piotr Malinowski, Grzegorz L. Kałuża, Patrick W. Serruys	19
8	Acute referral of patients from general practitioners: should the hospital doctor or a nurse receive the call? 2011 ·Scandinavian Journal of Trauma Resuscitation and Emergency Medicine ·Christian Backer Mogensen, (unknown), Peter Stæhr	2
9	Drug-related problems in general practice: results from a development project in Denmark 2006 ·Pharmacy World & Science ·(unknown), (unknown), (unknown), Hanne Herborg, Jakob Kjellberg, Peter Stæhr	21
10	AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes 2004 ·American Journal of Physiology-Endocrinology and Metabolism ·Kurt Højlund, Kirsty J. Mustard, Peter Stæhr, D. Grahame Hardie, Henning Beck‐Nielsen, Erik A. Richter, Jørgen F. P. Wojtaszewski	71
11	The Role of the Liver in Type 2 Diabetes 2004 ·Reviews in Endocrine and Metabolic Disorders ·Peter Stæhr, Ole Hother‐Nielsen, Henning Beck‐Nielsen	23
12	GLUT4 expression in human muscle fibres is not correlated with intracellular triglyceride (TG) content. Is TG a maker or a marker of insulin resistance? 2003 ·Apmis ·Michael Gaster, P D Ottosen, Werner Vach, Hans Christiansen, Peter Stæhr, Henning Beck‐Nielsen, Henrik Daa Schrøder	14
13	Measurement of Fractional Whole-Body Gluconeogenesis in Humans From Blood Samples Using 2H Nuclear Magnetic Resonance Spectroscopy 2003 ·Diabetes ·Olaf Kunert, Harald Stingl, (unknown), (unknown), Elisabeth Bernroider, (unknown), Klaus Zangger, Peter Stæhr, Visvanathan Chandramouli, Bernard R. Landau, P. Nowotny, W. Waldhäusl, Ernst Haslinger, Michael Roden	29
14	Does overnight normalization of plasma glucose by insulin infusion affect assessment of glucose metabolism in Type 2 diabetes? 2003 ·Diabetic Medicine ·Peter Stæhr, Kurt Højlund, Ole Hother‐Nielsen, Jens J. Holst, (unknown)	2
15	Is hepatic glucose production increased in type 2 diabetes mellitus? 2002 ·Current Diabetes Reports ·Henning Beck‐Nielsen, Ole Hother‐Nielsen, Peter Stæhr	31
16	Hepatic glucose production: therapeutic target in type 2 diabetes? 2002 ·Diabetes Obesity and Metabolism ·Peter Stæhr, Ole Hother‐Nielsen, Henning Beck‐Nielsen	22
17	Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes 2002 ·European Journal of Clinical Investigation ·Kurt Højlund, Mikael Kjær Poulsen, Peter Stæhr, Klaus Brusgaard, Henning Beck‐Nielsen	26
18	Induction of GLUT-1 protein in adult human skeletal muscle fibers 2000 ·American Journal of Physiology-Endocrinology and Metabolism ·Michael Gaster, Jesper Franch, Peter Stæhr, Henning Beck‐Nielsen, Shad B. Smith, Henrik Daa Schrøder	16
19	Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects 1996 ·Diabetologia ·Dorte Worm, J. Vinten, Peter Stæhr, Jan Erik Henriksen, Aase Handberg, Henning Beck‐Nielsen	29
20	[Duplication in a medical department of tests previously performed in a primary sector]. 1992 ·PubMed ·(unknown), Lene Meldgaard Knudsen, Peter Stæhr	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact